Cel-Sci Corporation - CVM

Cel-Sci Corporation (CVM)
http://www.cel-sci.com/
Coverage: June 13, 2009 - December 13, 2009
Featured: June 13, 2009

The WHO (I'm not kidding- World Health Organization) has officially declared the Swine Flu as a world wide pandemic. This past week, the WHO raised the Swine Flu to "Phase 6", it's highest level for global risk. The Phase 6 alert does not mean the severity is increasing- it means the spread is more global. The Phase 6 ranking opens the door to accelerated production and research on a number of possible therapies and vaccines.

One company getting major recognition for a possible therapy is AMEX listed Cel-Sci (AMEX: CVM), a stock I have been following on and off for many years. Last week, CVM announced its L.E.A.P.S (Ligand Epitope Antigen Presentation System) technology, could represent an immune based therapy for swine flu, and had shown promise. At the Naval Medical Research Center in Silver Spring, MD, L.E.A.P.S has demonstrated an ability to enhance the body's natural protection against many different kinds of diseases. The Navy is focused on using the therapy to treat Malaria. This past week, Cel-Sci announced it was developing an immune based treatment for the Swine Flu, and the stock went absolutely ballistic.

Cel-Sci traded 32 million shares in one day last week, the highest volume in its more than 20 years of being a publicly traded company under the ticker CVM. CVM also surged from about $.25 to $.80 in one day. Pretty crazy.

Latest Newsletter Editions

spacer
Sat, Jan 16, 2010 @ 09:01 am
The Biotech Buzz Rerun I looked for some recent small stock biotech winners. Check out the action in ECTE of late. $1.30 to $2.20 this month on increasing volume as the stock climbs the charts. There's a lot of action in these small biotechs right now. Do you believe in reincarnation? In the stock market...
Wed, Jan 13, 2010 @ 11:01 am
The China/Biotech Buzz It's been a very strong week for my China ideas, with several of the top choices delivering strong news and making new all time highs this week. Review and comments on the hot China ideas below. Biotechs are buzzing right now, and a great number of small cap/biotech stocks are...
Wed, Dec 2, 2009 @ 08:12 am
Coming Attractions You might recall an edition I published about a month ago suggesting it was time to step back, take a look at every idea, and set some cash aside to get past tax selling season and into December. The time has come. I suspect December will be a good month in the markets. Small stocks...
Mon, Nov 9, 2009 @ 02:11 pm
You Asked For It; You'll Get It As expected, lots of you read about my Interclick (NASDAQ: ICLK) idea over the weekend, and sent me the same comment: Why didn't you tell us about this one back in May when it was still under $1 on the Bulletin Board? Point taken- after all, isn't that the goal of investing...
Sat, Oct 10, 2009 @ 04:10 pm
A Couple More Updates: Cel-Sci (AMEX: CVM) and CalAmp (NASDAQ: CAMP) There's lots more action to cover from this past week, so let's get to two more of the actively traded ideas I have shared of late. Cel-Sci (NYSE AMEX: CVM): The Squawking and Finger Pointing Was Inevitable CVM, one of the hottest...

Click Here For More Newsletters on CVM

spacer

Latest Blog Entries

spacer

Quote Data

spacer
Last Trade: 0.65 Bid: 0.0000
Last Size: 0 Ask: 0.0000
Trade Time: 4:01pm Bid x Ask Size: N/A
Change: +0.0000 (+0.00%) Day's Range: 0.00 - 0.00
Prev Close: 0.6500 52wk Range: 0.54 - 1.27
Open: 0.0000 P/E (ttm): N/A
Volume: 0 EPS (ttm): -0.43
spacer [Chart]

Business Summary

spacer
CEL-SCI Corporation, a biotechnology company, engages in research and development of drugs and vaccines for the treatment of cancer and infectious diseases. The company’s primary product Multikine is a patented immunotherapeutic agent consisting of a mixture of naturally occurring cytokines under phase II clinical trail for the treatment of cancer. It also develops CEL-1000 peptide product with its Ligand Epitope Antigen Presentation System technology which is under preclinical stage for the protection/treatment of animals against herpes, malaria, viral encephalitis, and cancer. The company markets its products to cancer centers, physicians, and clinics involved in immunotherapy. CEL-SCI was founded in 1983 and is based in Vienna, Virginia.

Disclosure

spacer
TGR Group LLC, an affiliate of MarketByte LLC, has been paid a fee of 100,000 newly issued restricted shares by Cel-Sci Corporation, for coverage of the Company.

Recent News Headlines

spacer
CEL SCI CORP Files SEC form 8-K, Entry into a Material Definitive Agreement
Wed, 01 Jul 2015 21:11:52 GMT
CEL-SCI Reports June Patient Enrollment in Its Phase 3 Head and Neck Cancer Trial
Wed, 01 Jul 2015 13:20:00 GMT
[Business Wire] - CEL-SCI Corporation today announced that in June it has enrolled 25 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine* in just diagnosed, not yet treated patients with head and neck cancer.
CEL SCI CORP Files SEC form 8-K, Change in Directors or Principal Officers
Tue, 30 Jun 2015 17:12:44 GMT
CEL-SCI Corporation (NYSE MKT: CVM), Arguably the Most Undervalued Phase III Biotech, is Updated in Flaherty Special Situation Newsletter as Bob F's Best Buy
Mon, 29 Jun 2015 12:15:00 GMT
[Accesswire] - WEST HARRISON, NY / ACCESSWIRE / June 29, 2015 / CEL-SCI Corporation, (NYSE MKT: CVM), arguably the most undervalued Phase III biotech company, is featured in the June 25 issue of Flaherty Special Situation ...
CEL SCI CORP Financials
Sat, 27 Jun 2015 17:04:07 GMT
CEL SCI CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Tue, 23 Jun 2015 15:07:40 GMT
NEW STORY CEL-SCI to Present at the 2015 Bio International Convention
Tue, 16 Jun 2015 13:47:18 GMT
[at noodls] - CEL-SCI TO PRESENT AT THE 2015 BIO INTERNATIONAL CONVENTION Vienna, VA, June 16, 2015 -- CEL-SCI Corporation (NYSE MKT: CVM) ('CEL SCI' or the 'Company'), a late-stage cancer immunotherapy company, today ...
CEL-SCI to Present at the 2015 BIO International Convention
Tue, 16 Jun 2015 12:30:00 GMT
[Business Wire] - CEL-SCI Corporation , a late-stage cancer immunotherapy company, today announced that it will present at the 2015 BIO International Convention on Wednesday, June 17, 2015.
NEW STORY CEL-SCI is Cleared to Start Patient Enrollment for Its Phase 3 Cancer Immunotherapy Trial in Thailand
Mon, 08 Jun 2015 13:37:09 GMT
[at noodls] - CEL-SCI IS CLEARED TO START PATIENT ENROLLMENT FOR ITS PHASE 3 CANCER IMMUNOTHERAPY TRIAL IN THAILAND Thailand is 24th country to clear CEL-SCI's trial for patient enrollment Vienna, VA, June 8, 2015 -- ...
CEL-SCI is Cleared to Start Patient Enrollment for Its Phase 3 Cancer Immunotherapy Trial in Thailand
Mon, 08 Jun 2015 13:00:00 GMT
[Business Wire] - VIENNA, Va.--(BUSINESSWIRE)-- CEL-SCI Corporation (NYSE MKT: CVM) (“CEL SCI” or the “Company”) today announced that CEL-SCI is now cleared to start patient enrollment in Thailand in its ongoing Phase 3 trial with its investigational cancer immunotherapy Multikine* (Leukocyte Interleukin, Injection) in patients with advanced primary (not yet treated) head and neck cancer. Thailand is the 24th country to authorize CEL-SCI’s Phase 3 trial for patient enrollment. “We have now completed enrollment of over 50% of the anticipated 880 patients in our Phase 3 trial and continue to expand the trial into more sites to increase the rate of enrollment.
CEL-SCI is Cleared to Start Patient Enrollment for Its Phase 3 Cancer Immunotherapy Trial in Thailand
Mon, 08 Jun 2015 13:00:00 GMT
[Business Wire] - CEL-SCI Corporation today announced that CEL-SCI is now cleared to start patient enrollment in Thailand in its ongoing Phase 3 trial with its investigational cancer immunotherapy Multikine* in patients with advanced primary head and neck cancer.
NEW STORY CEL-SCI Reports May Patient Enrollment in Its Phase 3 Head and Neck Cancer Trial
Mon, 01 Jun 2015 14:34:14 GMT
[at noodls] - CEL-SCI REPORTS MAY PATIENT ENROLLMENT IN ITS PHASE 3 HEAD AND NECK CANCER TRIAL Over 50% of patients have now been enrolled in the trial Vienna, VA, June 1, 2015 -- CEL-SCI Corporation (NYSE MKT: CVM)('CEL ...
CEL-SCI Reports May Patient Enrollment in Its Phase 3 Head and Neck Cancer Trial
Mon, 01 Jun 2015 14:05:00 GMT
[Business Wire] - CEL-SCI Corporation today announced that in May it has enrolled 26 patients in its ongoing Phase III trial of its investigational immunotherapy Multikine* in patients with advanced primary squamous cell carcinoma of the oral cavity/soft palate, a type of head and neck cancer.
NEW STORY CEL-SCI Announces Closing of Public Offering for Gross Proceeds of $16 Million
Fri, 29 May 2015 20:26:15 GMT
[at noodls] - CEL-SCI ANNOUNCES CLOSING OF PUBLIC OFFERING FOR GROSS PROCEEDS OF $16 MILLION Vienna, VA, May 29, 2015 -- CEL-SCI Corporation (NYSE MKT: CVM)('CEL SCI' or the 'Company') today announced that it has closed ...
CEL SCI CORP Files SEC form 8-K, Entry into a Material Definitive Agreement
Fri, 29 May 2015 14:09:30 GMT
CEL-SCI Announces Closing of Public Offering for Gross Proceeds of $16 Million
Fri, 29 May 2015 12:00:00 GMT
[Business Wire] - CEL-SCI Corporation today announced that it has closed a best efforts offering of 20,253,164 shares of common stock and 20,253,164 warrants to purchase shares of common stock.
NEW STORY CEL-SCI to Present at the 2015 Marcum MicroCap Conference
Wed, 27 May 2015 15:59:03 GMT
[at noodls] - CEL-SCI TO PRESENT AT THE 2015 MARCUM MICROCAP CONFERENCE Vienna, VA, May 27, 2015 -- CEL-SCI Corporation (NYSE MKT: CVM), a late-stage cancer immunotherapy company, today announced that it will present ...
CEL-SCI to Present at the 2015 Marcum MicroCap Conference
Wed, 27 May 2015 15:18:00 GMT
[Business Wire] - CEL-SCI Corporation , a late-stage cancer immunotherapy company, today announced that it will present at the 2015 Marcum MicroCap Conference on Thursday, May 28, 2015 in New York City at the Grand Hyatt Hotel.
CEL SCI CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and E
Tue, 26 May 2015 10:01:32 GMT
NEW STORY CEL-SCI Prices Up To $16 Million Public Offering of Common Stock and Warrants
Fri, 22 May 2015 13:50:10 GMT
[at noodls] - CEL-SCI PRICES UP TO $16 MILLION PUBLIC OFFERING OF COMMON STOCK AND WARRANTS Vienna, VA, May 22, 2015 -- CEL-SCI Corporation (NYSE MKT: CVM)('CEL SCI' or the 'Company') today announced that it has priced ...